News Releases

News & Events

News Releases

Synteract Proves Industry Expertise Through Conference and Webinar Education

SAN DIEGO – Sept. 1, 2016 – Executives from Synteract, a full-service, international contract research organization (CRO), will participate in several speaking engagements and presentations this fall: an FDANews webinar on September 7, the Outsourcing Clinical Trials New England conference on September 7-8, the FierceBiotech Drug Development Forum on September 19-21, and the Disruptive Innovations US, better known as DPharm, conference on September 20-21. Each event brings together thought leaders in the clinical research industry to understand major changes and discuss best practices.

Dr. Martine Dehlinger-Kremer, Global Vice President, Medical & Regulatory Affairs for Synteract and the chair of the pediatric working group for EUCROF, will discuss latest compliance developments and how they affect pediatric research requirements for both the FDA and EMA in her webinar entitled “Pediatric Clinical Trials Regulation: Latest FDA and International Compliance Developments”. The online-accessible session runs from 1:30-3:00 p.m. EDT on Sept. 7th. Registration details are available at this link:

At OCT New England, Synteract Director of Regulatory Affairs Dr. Ludwig Baumann will present “The New EU Clinical Trials Regulation: The Impact It Will Have for US Sponsors Running Global Trials” from 10:00-10:30 a.m. EDT on day one of the event, September 7. In his presentation, Dr. Baumann will address important differences between the EMA’s and FDA’s expectations, among other key aspects.

Vice President, Strategic Development Etienne Drouet will present at the FierceBiotech Drug Development Forum on the “Partnerships in Immuno-Oncology” panel from 10:00-10:50 a.m. EDT on Tuesday, September 20. This discussion involves cancer immunotherapies, a growing trend in clinical research, and how the market surrounding these drugs will evolve in coming years.

Finally, Synteract Project Director Cheryl Johnson will speak on the “Innovative Sources and Solutions” track of the “Innovation in Problem Solving” segment of DPharm, September 20. Here, Johnson will present a problem within clinical research and offer Synteract’s process for providing a solution, with the goal of inspiring collaboration between different sides of clinical research.

Attendees interested in meeting with the Synteract team at these events may contact Executive Director of Business Development Kim Martinez at 760-529-3440 or

See Synteract's full schedule of events and follow its social channels on LinkedIn and Twitter for live updates during all conferences.

About Synteract
Synteract is a full-service contract research organization with a successful two-decade track record supporting biotechnology, medical device and pharmaceutical companies in all phases of clinical development. Synteract has conducted Phase I-IV studies on six continents and 60 countries, offering expertise across multiple therapeutic areas, with notable depth in oncology, immunotherapy, CNS, infectious disease, endocrinology, cardiovascular and respiratory, among other indications. With its “Shared Work – Shared Vision” philosophy, Synteract provides customized services collaboratively and cost effectively, ensuring on-time delivery of quality data to help bring tomorrow’s treatments to patients.

# # #
Beth Walsh


Contact Synteract

Tell us how to stay in touch with you: